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INTRODUCTION
There are many community-based
studies on the prevalence of diabetes,
impaired glucose tolerance (IGT) and
impaired fasting glucose (IFG). However,
studies on the prevalence of IGT and
diabetes unknown in patients with IFG, by
75-g oral glucose tolerance test (OGTT),
are few and small.
OBJECTIVE
1) To estimate the prevalence of unknown
diabetes and IGT in patients with IFG by OGTT. 
2) To determine the percentage of patients
diagnosed of unknown diabetes having a glicated
hemoglobin (A1C) value consistent with the
diagnosis of diabetes according to ADA (A1c ≥ 
6.5 %).
RESULTS
779 patients (47.7 % male). Mean (95% confidence interval): AGE male: 63.9 (62.9-64.9); female: 
64.5 (63.6-65.5). BODY MASS INDEX : male: 30.5 (30.1-30.9); female: 31.3 (30.8-31.8). The 
prevalence of  UNKOWN DIABETES  (119 subjects) was 15.3 % (12.7%-17.9%). Of them, only 32 
(27 %) had criteria of diabetes according to A1C values. The prevalence of IGT was 28 % (24.8%-
31.2%).
CONCLUSIONS:
1) The prevalence of unknown diabetes and impaired glucose tolerance in patients with
impaired fasting glucose is relevant, so 75-g oral glucose tolerance test would be
advisable systematically perform in these patients, especially those with risk factors
for diabetes. 
2) A1c had only been able to detect diabetes in approximately one third of the subjects 
that had it.
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METHODS
Cross-sectional study, nested in a randomized trial (PREDIABOLE. ISRCTN03372660). 779 patients 
with IFG referred by family physicians for entry into PREDIABOLE trial. Outcomes variables: plasma 
glucose  after OGTT, and A1C
